Prasinezumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | α-Synuclein |
| Clinical data | |
| Other names | NEOD002; NEOD-002; PRX002; PRX-002; RG7935; RG-7935; RO7046015; RO-7046015 |
| Routes of administration | Intravenous |
| Drug class | Monoclonal antibody |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Prasinezumab (INN, USAN; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease.[1][2][3][4] No significant effect on disease progression was seen in a 52-week phase 2 clinical trial.[5]There have been concerns about research misconduct and data fabrication relevant to prasinezumab.[6] [2]
As of May 2024, prasinezumab is in phase 3 clinical trials for Parkinson's disease.[1][7] It is under development by Prothena Biosciences and Roche.[1]
- ^ a b c "Prasinezumab - Prothena Corporation/Roche - AdisInsight". adisinsight.springer.com. Retrieved 4 July 2025.
- ^ a b Manoutcharian K, Gevorkian G (1 March 2024). "Recombinant Antibody Fragments for Immunotherapy of Parkinson's Disease". Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 38 (2): 249–257. doi:10.1007/s40259-024-00646-5. ISSN 1179-190X. PMC 10912140. PMID 38280078.
- ^ Lasheen NN, Allam S, Elgarawany A, Aswa DW, Mansour R, Farouk Z (September 2024). "Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders". The Journal of Physiological Sciences : JPS. 74 (1) 46: 46. doi:10.1186/s12576-024-00933-4. PMC 11421184. PMID 39313800.
- ^ Teng JS, Ooi YY, Chye SM, Ling AP, Koh RY (2021). "Immunotherapies for Parkinson's Disease: Progression of Clinical Development". CNS & Neurological Disorders Drug Targets. 20 (9): 802–813. doi:10.2174/1871527320666210526160926. PMID 34042040.
- ^ Manoutcharian K, Gevorkian G (March 2024). "Recombinant Antibody Fragments for Immunotherapy of Parkinson's Disease". Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 38 (2): 249–257. doi:10.1007/s40259-024-00646-5. PMC 10912140. PMID 38280078.
- ^ Incorvaia D (26 September 2024). "NIH neuroscience leader committed research misconduct, agency investigation finds". Fierce Biotech. Retrieved 26 September 2024.
- ^ "Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease". www.roche.com. Retrieved 4 July 2025.